Colorectal Cancer

A phase 3 trial designed to assess trifluridine and tipiracil plus bevacizumab as first-line treatment for certain patients with advanced colorectal cancer missed its primary endpoint.

Patients with pediatric onset inflammatory bowel disease may have a higher risk for cancer and death, according to a presentation at UEG Week Virtual 2021.

Healio Gastroenterology presents the following report on the top stories from UEG Week 2021.

In a recent study, researchers found that antihypertensive drugs could potentially reduce mortality among patients with stage I to stage III colorectal cancer. It was the top story in hematology/oncology last week.

Low-cost antihypertensive drugs appeared associated with reductions in colorectal cancer-specific mortality among patients with stage I to stage III disease, according to results of a retrospective analysis published in Cancer Medicine.

Amid lockdowns, many countries implemented a suspension of routine surveillance for colorectal cancer, resulting in fewer diagnoses in older patients with more complications, according to a presentation during UEG Week Virtual.

The FDA approved cetuximab in combination with encorafenib for treatment of certain patients with colorectal cancer.

People with MS had lower overall and cancer-specific survival soon after colorectal cancer diagnosis compared with those without MS, according to results of a retrospective matched cohort study published in Neurology.

The American Gastroenterological Association published a conceptual model and clinical practice update for the prevention, detection and management of colorectal dysplasia in patients with inflammatory bowel disease.

Incidence of early-onset colorectal cancer has increased in the United States over the past 2 decades, but trends vary considerably by race and ethnicity, according to study results published in Clinical Gastroenterology and Hepatology.